Evaluation of the relative bioavailability between two formulations of olmesartan medoxomil 40mg, in orodispersible tablet form and coated tablet form, in healthy participants of both sexes [PDF]
The objective of this study was to verify whether the test formulation of olmesartan medoxomil, in orodispersible tablet form, administered with water (treatment B) and without water (treatment C), presents a rate and extent of absorption equivalent to ...
Guilherme Guimarães de Souza +7 more
semanticscholar +4 more sources
Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar®) in older patients with essential hypertension: Subgroup analysis from the Sevikar study [PDF]
Essential hypertension is a notable threat for the older (age, ≥65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential ...
Zhao-Qiang Cui +39 more
semanticscholar +2 more sources
Host–Guest Interaction Study of Olmesartan Medoxomil with β-Cyclodextrin Derivatives [PDF]
Olmesartan medoxomil (OLM) is a selective angiotensin II receptor antagonist used in the treatment of hypertension. Its therapeutic potential is limited by its poor water solubility, leading to poor bioavailability. Encapsulation of the drug substance by
M. Andor +15 more
semanticscholar +2 more sources
Efficacy and safety of olmesartan medoxomil‐amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single‐arm, multi‐center, real‐world study [PDF]
There lacks real‐world study with a large sample size assessing olmesartan medoxomil‐amlodipine besylate (OM‐AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM‐AML tablet in patients with essential hypertension.
Zhao-Qiang Cui +39 more
semanticscholar +2 more sources
Host–Guest Complexation of Olmesartan Medoxomil by Heptakis(2,6-di-O-methyl)-β-cyclodextrin: Compatibility Study with Excipients [PDF]
Background: Olmesartan medoxomil (OLM) is the prodrug of olmesartan, an angiotensin II type 1 receptor blocker that has antihypertensive and antioxidant activities and renal protective properties.
D. Man +12 more
semanticscholar +2 more sources
Synthesis and Characterization of Process-Related Impurities of Antihypertensive Drug Olmesartan Medoxomil [PDF]
Olmesartan medoxomil (1) is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, three process-related impurities were observed along with the final API.
G. Venkanna +5 more
doaj +2 more sources
Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments [PDF]
Olmesartan medoxomil (OLM) is one of the prominent antihypertensive drug that suffers from low aqueous solubility and dissolution rate leading to its low bioavailability.
Bjad K. Almutairy +5 more
semanticscholar +2 more sources
Acute quadruple extremity compartment syndrome due to angio-oedema after polypharmacy overdose including olmesartan medoxomil, telmisartan and vildagliptin [PDF]
This case report describes a rare manifestation of acute compartment syndrome (ACS) involving all four extremities, precipitated by angio-oedema in a middle-aged woman who consumed an overdose of multiple medications: nifedipine, azelnidipine, amlodipine
Yumi Kono +3 more
semanticscholar +2 more sources
Olmesartan medoxomil: current status of its use in monotherapy
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist.
Hans R Brunner
doaj +2 more sources
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
Mark GreathouseSouth Hills Cardiology Associates of Pittsburgh, Pittsburgh, PA, USAAbstract: In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When
Mark Greathouse
doaj +1 more source

